Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise against tough cancers

NCT ID NCT03530397

Disease control Sponsor: MedImmune LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 participants will take part to help researchers understand how well the drug works and what side effects may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

400 people

The number who actually took part.

Started

Apr 2018

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Age ≥ 18 years at the time of screening 2. World Health Organization/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment 3. Life expectancy ≥ 12 weeks 4. Histologically or cytologically-confirmed advanced solid tumors 5. Subjects who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy or any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment may be eligible to enter the study following a washout period as applicable 6. Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception 7. Nonsterilized males who are sexually active with a female partner of childbearing potential must use a male condom with spermicide where locally available from Day 1 and for 90 days after the final dose of investigational product. Males receiving pemetrexed or carboplatin must use contraception during study treatment and up to 6 months thereafter. 8. Subjects must have at least one measurable lesion 9. Adequate organ and marrow function 10. Written informed consent and any locally required authorization 11. Subjects must provide tumor material as applicable Exclusion Criteria 1. Involvement in the planning and/or conduct of the study (applies to both MedImmune staff and/or staff at the study site) 2. Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow-up period of an interventional study 3. For subjects who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4: 1. Subjects must not have received anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other immunotherapy or immune-oncology (IO) agent within 21 days of commencing treatment with investigational product. 2. Subject must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy. 3. All AEs while receiving prior immunotherapy must have completely resolved or resolved to Grade 1 prior to screening for this study. 4. Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product is excluded. 5. Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational product. 6. Active or prior documented autoimmune or inflammatory disorders 7. History of active primary immunodeficiency: 8. History of organ transplant 9. Known allergy or reaction to any component of the planned study treatment. 10. Untreated CNS metastatic disease, leptomeningeal disease, or cord compression 11. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v4.03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria 12. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of Investigational Product or still recovering from prior surgery 13. Female subjects who are pregnant or breastfeeding, as well as male or female subjects of reproductive potential who are not willing to employ one highly effective method of birth control 14. Uncontrolled intercurrent illness, that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the subject to give written informed consent. 15. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of the subject's safety or study results 16. Judgment by the investigator that the subject is unsuitable to participate in the study and the subject is unlikely to comply with study procedures, restrictions, and requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Selected advanced solid tumors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm type 1 diabetes mellitus 12

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Selected advanced solid tumors

Contacts and locations

Locations

  • Research Site

    Detroit, Michigan, 48202, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Chapel Hill, North Carolina, 27599, United States

  • Research Site

    Providence, Rhode Island, 02903, United States

  • Research Site

    Chattanooga, Tennessee, 37404, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Melbourne, 3000, Australia

  • Research Site

    Melbourne, 3004, Australia

  • Research Site

    Randwick, 2031, Australia

  • Research Site

    Bordeaux, 33075, France

  • Research Site

    Lyon, 69373, France

  • Research Site

    Villejuif, 94805, France

  • Research Site

    Meldola, 47014, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Ravenna, 48121, Italy

  • Research Site

    Roma, 168, Italy

  • Research Site

    Amsterdam, 1066 CX, Netherlands

  • Research Site

    Lisbon, 1649-035, Portugal

  • Research Site

    Porto, 4200-072, Portugal

  • Research Site

    Cheongju-si, 28644, South Korea

  • Research Site

    Gyeonggi-do, 13620, South Korea

  • Research Site

    Incheon, 21565, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    A Coruña, 15006, Spain

  • Research Site

    Barcelona, 08003, Spain

  • Research Site

    Barcelona, 08028, Spain

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Barcelona, 08041, Spain

  • Research Site

    Barcelona, 08916, Spain

  • Research Site

    Majadahonda, 28222, Spain

  • Research Site

    Málaga, 29010, Spain

  • Research Site

    Pamplona, 31008, Spain

  • Research Site

    Valencia, 46010, Spain

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Taipei, 10048, Taiwan